NewTimeSpace (newtimespace.com) reported that on August 3, 2026, the chip theme weakened, with SMIC (00981.HK) fluctuating lower. As of 13:20, the stock was quoted at HKD 61.900, down 2.13%.
NewTimeSpace News: Metis TechBio Co., Ltd. (07666.HK) announced a collaboration with HENGRUI PHARMA for the localized deployment of its AiTEM AI formulation platform at Hengrui. Driven by the Company's proprietary NanoForge nano-delivery engine, the platform has previously shortened the formulation optimization cycle from 1–2 years to just 3 months. The Company, which went public in May 2026, is recognized as the "world's first AI-powered drug delivery public company."
NewTimeSpace (newtimespace.com) reported that on August 3, 2026, the robotics theme strengthened, with UBTECH (09880.HK) fluctuating higher. As of 13:12, the stock was quoted at HKD 84.050, up 3.07%.
NewTimeSpace News: InSilico Medicine announced that its oral NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Bio and empowered by the generative AI platform Chemistry42, received NMPA IND approval for Parkinson's disease treatment, marking the formal launch of parallel clinical evaluations in China and Australia; the blood-brain barrier-penetrating candidate achieved PCC nomination in December 2024, FDA IND approval in January 2026, first human dosing in Australia in June 2026, and NMPA IND approval in July 2026.
NewTimeSpace News: AIM Vaccine announced that its wholly-owned subsidiary AIM Honor has completed supplementary data submission to the CDE for its serum-free iterative rabies vaccine (CXSS2500044) following successful on-site inspections, with Phase III results demonstrating good safety, immunogenicity, and immune persistence; the vaccine eliminates animal serum components to significantly reduce adverse reaction rates; the China rabies vaccine market is expected to reach RMB 14.8 billion by 2030, and the group has completed international-standard facility construction and commercial-scale validation production.
NewTimeSpace News: LeadsBiolabs announced that its self-developed WeilixinTM (PD-L1/4-1BB bispecific antibody opatisumab, LBL-024) received CDE IND approval for metastatic colorectal cancer (mCRC) to initiate an open-label, multi-center Phase Ib/II study; the drug simultaneously blocks the PD-1/PD-L1 pathway and conditionally activates the 4-1BB pathway, with prior clinical activity validated across EP-NEC, NSCLC, SCLC, and BTC; the company has launched 13 solid tumor indication studies in China, and WeilixinTM, as the world's first 4-1BB-targeting molecule in pivotal single-arm registrational trials, has received CDE Breakthrough Therapy, FDA Orphan Drug, and Fast Track designations.
On July 31, 2026, The Hang Seng Index edged up 0.10%, the Hang Seng Tech Index rose 0.53%, while the Hang Seng China Enterprises Index dipped 0.38%. The large-model sector rallied broadly. Zhipu (02513.HK) surged as much as over 28% in early trading, while MINIMAX-W (00100.HK) gained more than 13% after MiniMax officially launched its new multimodal generation model, MiniMax H3, and announced that it would be open-sourced in the near future – marking the company's first open-source multimodal generation model.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the NMPA has approved the clinical trial application for HLX43 for Injection, a PD-L1-targeted antibody-drug conjugate (ADC), in combination with bevacizumab with or without chemotherapy for the treatment of advanced/metastatic solid tumors. Previously, at the ASCO 2026 Annual Meeting, HLX43 demonstrated a confirmed objective response rate of 36.8% in EGFR wild-type non-squamous NSCLC patients.
NewTimeSpace News: On 31 July 2026, RoboSense (02498.HK) rallied sharply in the afternoon session. As at 14:51, the stock traded at HK$23.80, representing an intraday gain of 7.89%. China’s cumulative sales of passenger vehicles equipped with L2 and above advanced driver-assistance systems (ADAS) hit 15.1537 million units in 2025, with a market penetration rate of 66.12%, up more than 10 percentage points from 2024. The penetration rate climbed further to 70.12% in the first three months of 2026.
NewTimeSpace (newtimespace.com) reported that on July 31, 2026, the chip theme rebounded sharply, with HUA HONG GRACE(01347.HK) fluctuating higher. As of 13:21, the stock was quoted at HKD 132.200, up 5.34%.
NewTimeSpace (newtimespace.com) reported that on July 31, 2026, the robotics theme strengthened significantly, while Midea Group (00300.HK) fluctuated lower. As of 13:10, the stock was quoted at HKD 98.200, down 0.71%.
NewTimeSpace News: Lee's Pharmaceutical announced on 30 July that the Investigational New Drug (IND) application filed by the Group in China for its proprietary ADC asset ZK2401 has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (NMPA).
NewTimeSpace News: Sirnaomics Ltd. (02257.HK) announced that the first patient has been successfully dosed in a Phase 2 multicenter clinical trial evaluating STP705 for medical aesthetics. The trial aims to systematically assess the clinical efficacy of STP705 in achieving targeted subcutaneous fat reduction through local administration, leveraging the Group's proprietary PNP oligonucleotide delivery platform, which enables site-specific gene regulation to drive controlled adipocyte clearance.
NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the first patient has been dosed in a Phase 1 clinical study in China for its self-developed HLX3902 Injection, a STEAP1×CD3×CD28 trispecific antibody, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors. To date, no trispecific antibody of the same target class has been approved for marketing globally.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained a drug manufacturing registration approval from the NMPA for Cimetidine Injection (2ml:0.2g), classified as a Category 3 chemical drug and deemed to have passed the consistency evaluation. The product is primarily indicated for the treatment of gastrointestinal ulcers. In addition, the Group has obtained a registration approval for Acetylcysteine Solution for Inhalation (3ml:0.3g), classified as a Category 4 chemical drug and deemed to have passed the consistency evaluation. The product is indicated for the treatment of respiratory diseases accompanied by excessive thick mucus secretions.
On July 30, 2026, Hong Kong's tech-themed stocks broadly weakened. The Hang Seng Index edged up 0.20%, while the Hang Seng Tech Index fell 1.25% and the Hang Seng China Enterprises Index gained 0.25%.The large-model sector showed mixed performance. Tencent Holdings (00700.HK) bucked the trend and rose 1.16%, with Meituan-W and Kuaishou-W also gaining. Among the two major large-model players, Zhipu (02513.HK) plunged over 15%, while MINIMAX-W fell more than 4%.
